PBE - ETF AI Analysis
Top Page
Invesco Dynamic Biotechnology & Genome ETF (PBE)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past three and twelve months, indicating positive momentum in its biotech holdings.
Leading Biotech Companies in Top Holdings
Several major positions like Amgen, Biogen, and Vertex have delivered solid year-to-date performance, helping support the fund’s returns.
Focused Exposure to Innovative Health Care
Almost all assets are invested in U.S. health care and biotech companies, giving investors targeted exposure to a high-innovation sector.
Negative Factors
High Sector Concentration
With nearly all assets in health care and biotech, the fund is heavily exposed to swings in one industry rather than being broadly diversified.
Mixed Performance Among Top Holdings
Some key holdings like Regeneron and Alnylam have shown weak year-to-date performance, which can drag on overall fund results.
Above-Average Expense Ratio
The fund’s fee is higher than many broad market ETFs, which means more of the returns are used to cover costs.
PBE vs. SPDR S&P 500 ETF (SPY)
AUM404.80M
RegionNorth America
Expense Ratio0.59%
Beta0.68
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield1.65%
Asset ClassEquity
Index TrackedDynamic Biotech & Genome Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume20,759
30 Day Avg. Volume27,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
123.94Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PBE Summary
PBE is the Invesco Dynamic Biotechnology & Genome ETF, which follows the Dynamic Biotech & Genome Intellidex Index. It focuses on U.S. health care companies working in biotechnology and genetics, including well-known names like Amgen and Gilead Sciences. Investors might consider PBE if they want growth potential from new medical treatments and drugs, while spreading their money across many biotech firms instead of picking single stocks. However, biotech stocks can be very volatile, often moving sharply on drug trial news or regulation changes, so the ETF’s price can go up and down a lot.
How much will it cost me?The expense ratio for the Invesco Dynamic Biotechnology & Genome ETF (PBE) is 0.58%, which means you’ll pay $5.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on specialized biotechnology and genomic research companies that require more in-depth analysis and management.
What would affect this ETF?The Invesco Dynamic Biotechnology & Genome ETF (PBE) could benefit from advancements in biotechnology and genomic research, as well as increased demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or economic downturns that could impact funding for biotech companies. The ETF’s focus on U.S.-based firms and top holdings like Vertex Pharmaceuticals and Gilead Sciences highlights its reliance on the performance of leading biotech innovators.
PBE Top 10 Holdings
PBE is a pure-play U.S. biotech fund, and its story right now is all about a handful of innovators setting the pace while a few riskier names wobble in the background. Heavyweights like Amgen, Regeneron, Vertex, Biogen, and Gilead are generally rising or steady, giving the ETF a solid core of profitable, research-driven giants. Royalty Pharma adds a more stable, cash-flow twist to the mix. On the flip side, speculative Omeros is still struggling, acting as a bit of a speed bump in an otherwise forward-leaning biotech lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Biogen | 5.22% | $21.16M | $32.08B | 49.90% | 74 Outperform | |
| Natera | 5.19% | $21.02M | $47.41B | 95.20% | 73 Outperform | |
| Gilead Sciences | 5.13% | $20.79M | $178.21B | 25.46% | 78 Outperform | |
| Royalty Pharma | 5.01% | $20.32M | $33.70B | 61.19% | 79 Outperform | |
| Regeneron | 4.98% | $20.18M | $80.46B | 39.55% | 78 Outperform | |
| Vertex Pharmaceuticals | 4.95% | $20.06M | $130.64B | 30.65% | 78 Outperform | |
| Illumina | 4.87% | $19.74M | $31.17B | 117.04% | 71 Outperform | |
| Amgen | 4.53% | $18.36M | $204.01B | 36.53% | 77 Outperform | |
| Sarepta Therapeutics | 3.13% | $12.69M | $2.16B | 17.60% | 51 Neutral | |
| Neurocrine | 2.95% | $11.96M | $15.88B | 10.11% | 80 Outperform |
PBE Technical Analysis
Positive
―
Price Trends
93.43
Positive
88.06
Positive
84.07
Positive
Market Momentum
0.24
Positive
44.69
Neutral
5.82
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 96.46, equal to the 50-day MA of 93.43, and equal to the 200-day MA of 84.07, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 44.69 is Neutral, neither overbought nor oversold. The STOCH value of 5.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBE.
PBE Peer Comparison
Comparison Results
Performance Comparison
PBE
Invesco Dynamic Biotechnology & Genome ETF
93.64
25.28
36.98%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents